1. Home
  2. Labeler Index
  3. Remedyrepack Inc.
  4. 70518-3497
  5. Product Images: Caplyta

Product Images Caplyta

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 6 images provide visual information about the product associated with Caplyta NDC 70518-3497 by Remedyrepack Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Remedy_Label - Remedy Label

Remedy_Label - Remedy Label

Caplyta (lumateperone) is a prescription medication that comes in a box with 30 capsules of 42 mg each. Its NDC number is 70518-3497-00 and it is sourced from NDC 72060-0142-40, manufactured by Intra-Cellular Therapies in New York, NY. The medication should be stored between 15-30°C (59-86°F) but not exceeding 20-25°C (88-77°F). More information on usage can be found in the Package Insert. It is important to keep this medication out of the reach of children. This medication was repackaged by RemedyRepack Inc. located in Indiana, PA.*

Chemical Structure - caplyta 1

Chemical Structure - caplyta 1

Figure 1: Effects of Intrinsic Factors on Lumateperone Pharmacokinetics - caplyta 2

Figure 1: Effects of Intrinsic Factors on Lumateperone Pharmacokinetics - caplyta 2

Figure 2: Effects of Other Drugs on Lumateperone Pharmacokinetics - caplyta 3

Figure 2: Effects of Other Drugs on Lumateperone Pharmacokinetics - caplyta 3

This appears to be a table showing fold change and 90% confidence intervals for different PK measures and inhibitors/inducers. The measures listed include Cmax and AUCt for various drugs, with corresponding inhibitors/inducers such as itraconazole, rifampin, and valproic acid. The values in the table range from 0.008 to 40, and there is a column indicating the change relative to a reference ratio.*

Figure 3: Change from Baseline in PANSS Total Score by Time (Weeks) in Patients with Schizophrenia in Study 2. - caplyta 4

Figure 3: Change from Baseline in PANSS Total Score by Time (Weeks) in Patients with Schizophrenia in Study 2. - caplyta 4

The text describes a graph showing the number of patients over time in weeks for Placebo and CAPLYTA 42 mg. The graph has two Y-axes, one for the number of patients and the other for an unidentified variable. The number of patients is shown on the Y-axis on the left, and the weeks are shown on the X-axis. The number of patients for Placebo decreases as time progresses, whereas the number of patients for CAPLYTA 42 mg is relatively constant. The text also includes a notation of "LS mean" which is related to the least squares mean.*

Figure 4. LS Mean* Change from Baseline in MADRS Total Score by Visits (Study 3) - caplyta 5

Figure 4. LS Mean* Change from Baseline in MADRS Total Score by Visits (Study 3) - caplyta 5

This is a chart showing the LS (least squares) mean change from baseline over a period of 6 weeks for both a placebo and CAPLYTA 42mg treatment in a group of patients. The number of patients included in each week is also provided.*

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.